Published in Cancer Biol Ther on April 14, 2008
Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol (2013) 1.67
IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol (2015) 1.08
Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model. PLoS One (2009) 0.99
The status of contemporary image-guided modalities in oncologic surgery. Ann Surg (2015) 0.97
Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2012) 0.88
Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging. J Healthc Eng (2013) 0.81
Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. Br J Neurosurg (2015) 0.77
CD147: a potential regulator of oncogenesis non-invasive imaging of CD147 in living subjects. Cancer Biol Ther (2008) 0.75
A clearer vision for in vivo imaging. Nat Biotechnol (2001) 10.49
Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res (1993) 3.62
Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res (2007) 3.25
Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res (2005) 2.42
Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res (2001) 2.33
Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med (2007) 2.16
Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 2.11
EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie (2005) 2.10
The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem (1995) 1.84
Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol (2002) 1.83
Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res (2007) 1.76
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer (2002) 1.56
Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther (2007) 1.52
In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope (2006) 1.50
A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Res (2006) 1.46
Expression of emmprin by oral squamous cell carcinoma. Int J Cancer (2000) 1.42
A histopathological appraisal of surgical margins in oral and oropharyngeal cancer resection specimens. Oral Oncol (2005) 1.35
Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg (2007) 1.33
Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett (2000) 1.27
Basigin (murine EMMPRIN) stimulates matrix metalloproteinase production by fibroblasts. J Cell Physiol (2001) 1.25
Increased EMMPRIN (CD 147) expression during oral carcinogenesis. Exp Mol Pathol (2005) 1.25
Head and neck tumors: imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol (2000) 1.24
Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope (2003) 1.22
Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther (2007) 1.16
Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin Radiat Oncol (2002) 1.15
Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem (1997) 1.09
Laryngeal or hypopharyngeal squamous cell carcinoma: can follow-up CT after definitive radiation therapy be used to detect local failure earlier than clinical examination alone? Radiology (2000) 1.06
Implications of tumour in resection margins following surgical treatment of squamous cell carcinoma of the head and neck. Clin Otolaryngol Allied Sci (1993) 1.06
Extracellular matrix metalloprotease inducer stimulates fibroblast-mediated tumor growth in vivo. Laryngoscope (2006) 0.95
Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope (2005) 0.95
Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol (2002) 0.93
Advances in head and neck imaging. Otolaryngol Clin North Am (2005) 0.83
Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol (2007) 3.54
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood (2007) 2.35
Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol (2013) 1.67
Patient-perceived and objective functional outcomes following transoral robotic surgery for early oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2011) 1.62
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Pretreatment, preoperative swallowing exercises may improve dysphagia quality of life. Laryngoscope (2006) 1.59
Robotic-assisted surgery for primary or recurrent oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2010) 1.52
Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts. Mol Cancer Ther (2007) 1.52
In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope (2006) 1.50
Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res (2008) 1.45
Dynasplint for the management of trismus after treatment of upper aerodigestive tract cancer: a retrospective study. Ear Nose Throat J (2011) 1.45
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck (2008) 1.42
Prevention of diabetic nephropathy in Ins2(+/)⁻(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J (2010) 1.40
Utility of CT surveillance for primary site recurrence of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.39
Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg (2007) 1.33
Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol (2003) 1.33
Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol (2012) 1.30
Functional outcomes after transoral robotic surgery for head and neck cancer. Otolaryngol Head Neck Surg (2009) 1.29
Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J Neurooncol (2007) 1.24
Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody. Radiology (2008) 1.20
A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature. J Ultrasound Med (2011) 1.19
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther (2007) 1.18
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res (2008) 1.17
The role of free tissue transfer in the reconstruction of massive neglected skin cancers of the head and neck. Arch Facial Plast Surg (2003) 1.17
Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer (2006) 1.16
Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther (2007) 1.16
Free tissue transfer to manage salvage laryngectomy defects after organ preservation failure. Laryngoscope (2007) 1.16
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res (2009) 1.16
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res (2007) 1.14
Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks. J Ultrasound Med (2010) 1.11
Transoral robotic-assisted surgery for head and neck squamous cell carcinoma: one- and 2-year survival analysis. Arch Otolaryngol Head Neck Surg (2010) 1.10
Assessment and incidence of salivary leak following laryngectomy. Laryngoscope (2012) 1.10
Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope (2011) 1.09
IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol (2015) 1.08
Gammadelta T cells in EAE: early trafficking events and cytokine requirements. Eur J Immunol (2009) 1.07
DCE-MRI detects early vascular response in breast tumor xenografts following anti-DR5 therapy. Mol Imaging Biol (2011) 1.07
Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope (2013) 1.04
A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res (2012) 1.04
Detection of early changes in renal function using 99mTc-MAG3 imaging in a murine model of ischemia-reperfusion injury. Am J Physiol Renal Physiol (2007) 1.03
Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol (2010) 1.02
Deficiency of P-selectin or P-selectin glycoprotein ligand-1 leads to accelerated development of glomerulonephritis and increased expression of CC chemokine ligand 2 in lupus-prone mice. J Immunol (2006) 1.02
Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Anal Biochem (2013) 1.00
Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg (2007) 1.00
Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity. Mol Endocrinol (2008) 0.99
Deletion of IGF-I receptor (IGF-IR) in primary osteoblasts reduces GH-induced STAT5 signaling. Mol Endocrinol (2010) 0.99
Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis (2004) 0.98
Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice. Otolaryngol Head Neck Surg (2013) 0.97
The status of contemporary image-guided modalities in oncologic surgery. Ann Surg (2015) 0.97
Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther (2011) 0.97
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res (2008) 0.97
Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope (2010) 0.97
(18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol (2012) 0.96
Extracellular matrix metalloprotease inducer stimulates fibroblast-mediated tumor growth in vivo. Laryngoscope (2006) 0.95
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther (2007) 0.95
Incidence and outcomes of stricture formation postlaryngectomy. Otolaryngol Head Neck Surg (2011) 0.95
Expandable tracheal stenting for benign disease: worth the complications? Ann Otol Rhinol Laryngol (2006) 0.94
Closure of post-laryngectomy pharyngocutaneous fistulae. Head Neck Oncol (2011) 0.94
Outcomes following temporal bone resection. Laryngoscope (2010) 0.93
Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther (2010) 0.93
EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck (2011) 0.93
Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma. Cancer Biol Ther (2013) 0.92
Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer. Arch Otolaryngol Head Neck Surg (2008) 0.92
Extracellular matrix metalloprotease inducer-expressing head and neck squamous cell carcinoma cells promote fibroblast-mediated type I collagen degradation in vitro. Mol Cancer Res (2005) 0.92
Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Mol Imaging (2011) 0.92
Free flap reconstruction of lateral mandibular defects: indications and outcomes. Otolaryngol Head Neck Surg (2011) 0.91
Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med (2014) 0.91
Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells. Mol Cancer Res (2011) 0.91
Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther (2008) 0.91
Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anticancer Drugs (2010) 0.91
Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg (2009) 0.90
Transoral robotic surgery for oropharyngeal and tongue cancer in the United States. Laryngoscope (2014) 0.90
Novel infectivity-enhanced oncolytic adenovirus with a capsid-incorporated dual-imaging moiety for monitoring virotherapy in ovarian cancer. Mol Imaging (2009) 0.90
CD147 and AGR2 expression promote cellular proliferation and metastasis of head and neck squamous cell carcinoma. Exp Cell Res (2012) 0.90
Primary versus delayed tracheoesophageal puncture for laryngopharyngectomy with free flap reconstruction. Laryngoscope (2011) 0.90
Zygomatic-maxillary buttress reconstruction of midface defects with the osteocutaneous radial forearm free flap. Head Neck (2008) 0.90
In vivo imaging of hepatic growth hormone signaling. Mol Endocrinol (2006) 0.90
Effect of anti-DR5 and chemotherapy on basal-like breast cancer. Breast Cancer Res Treat (2011) 0.90
Outcomes in head and neck reconstruction by surgical site and donor site. Laryngoscope (2013) 0.90
Influence of social support on health-related quality of life outcomes in head and neck cancer. Head Neck (2007) 0.90
Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs (2011) 0.89
Functional outcomes of fibula and osteocutaneous forearm free flap reconstruction for segmental mandibular defects. Laryngoscope (2010) 0.89
Management of the N0 neck in recurrent laryngeal squamous cell carcinoma. Laryngoscope (2010) 0.88
Outcomes of static and dynamic facial nerve repair in head and neck cancer. Laryngoscope (2010) 0.88
Current strategies in reconstruction of maxillectomy defects. Arch Otolaryngol Head Neck Surg (2011) 0.88
Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg (2012) 0.88